FAST NEWS: Ascletis Pharma’s loss narrows as core product sales surge
The latest: Ascletis Pharma Inc. (1672.HK) announced Tuesday its net loss narrowed sharply in the first half of this year to 16.56 million yuan ($2.3 million) from an 88 million…
Could Covid Drugs Help Cure Financial Ills at Ascletis Pharma?
Ascletis Pharma has applied for U.S. FDA approval to start clinical trials on a new Covid drug, ASC10 Key Takeaways: Ascletis Pharma is ready to put its new Covid drug…
FAST NEWS: Ascletis Pharma Files to Sell Ritonavir in Four European Countries
The latest: Ascletis Pharma Inc. (1672.HK) announced on Sunday that it has submitted marketing authorization applications for its oral ritonavir 100 mg film-coated tablets in Germany, France, Ireland and the…
RELATED ARTICLES
-
Facing revenue crisis, Ascletis Pharma tries to bulk up with obesity drugs
1672.HK -
Profit setback for Simcere Pharma in novel drugs quest
2096.HK
-
Novel drugs lift Sino Biopharm earnings, easing price-cap pain
1177.HK
-
CSPC Pharma weighs up diet drug for bigger bottom line
1093.HK
-
Shunned by investors, Henlius hangs up on its Hong Kong listing
2696.HK
-
CSPC Pharma taps R&D superstar in quest for new breakout drugs
1093.HK
